Skip to content
Review Open access

Bidirectional regulation between mitochondrial metabolic reprogramming and epigenetic modifications in renal tubular epithelial cell injury of diabetic kidney disease

Jul 2026 · Frontiers in Endocrinology · Vol 17 · 0 citations · 47 references
Medicine

TL;DR

A narrative review elaborates the closed-loop crosstalk between mitochondrial metabolism and epigenetics in tubular injury, highlights the therapeutic prospect of targeting this bidirectional regulatory axis, and provides novel theoretical evidence for revealing DKD pathogenesis and developing targeted intervention regimens.

Abstract

Background Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease (ESRD) worldwide. Renal tubular epithelial cell (RTEC) injury is a core driver of DKD initiation and progression. Mitochondrial metabolic reprogramming and epigenetic modification are two core events in DKD pathogenesis, and their bidirectional crosstalk has become a frontier and hot research topic in the pathogenesis of DKD. At present, the specific molecular mechanisms of their bidirectional regulation remain incompletely elucidated. Methods This narrative review collected literatures from PubMed, Web of Science and Embase up to March 2026. English original articles and reviews were included, whereas case reports, letters and non-English publications were excluded. We summarized the latest advances concerning the interaction between mitochondrial metabolic reprogramming and epigenetic modification in RTEC injury of DKD, focusing on their bidirectional molecular regulation. Results Key mitochondrial metabolic intermediates (acetyl-CoA, α-ketoglutarate (α-KG), nicotinamide adenine dinucleotide (NAD+)) act as substrates or cofactors of epigenetic enzymes to regulate DNA methylation, histone modifications, and noncoding RNA expression in RTECs. Epigenetic modifications in turn remodel mitochondrial biogenesis, fatty acid oxidation, and oxidative phosphorylation by regulating the expression of metabolism-related genes. Conclusion This narrative review elaborates the closed-loop crosstalk between mitochondrial metabolism and epigenetics in tubular injury, highlights the therapeutic prospect of targeting this bidirectional regulatory axis, and provides novel theoretical evidence for revealing DKD pathogenesis and developing targeted intervention regimens.

Read PDF

Similar papers

Review Aug 2026

Epigenetic regulation of tubular epithelial cell dysfunction in diabetic kidney disease.

In general, epigenetic regulation provides a new conceptual framework for understanding TEC dysfunction in DKD and provides a potential direction for the development of precision therapeutic strategies.

Hanxue Li, Meng-Meng Ma, Qiuyue Ren et al. · 0 citations
Review Open access Jul 2026

Metabolic Reprogramming and Immunometabolic Dysregulation in Diabetic Kidney Disease: From Pathogenesis to Precision Multi-target Therapies

Multi-omics integration and spatial transcriptomics hold promise for individualized and mechanism-guided interventions to halt diabetic kidney disease progression and propose precision strategies targeting mitochondrial homeostasis, ferroptosis inhibition, glycolytic blockade in immune cells, and multimodal therapies.

Zi-Yue Zhang, Yilun Qu, Xiaocheng Wang et al. · 0 citations
Review Open access Aug 2026

Natural products modulate renal metabolic reprogramming in diabetic kidney disease

This review systematically examines the mechanisms of metabolic reprogramming in different renal cell types and highlights their contribution to renal injury, highlighting the ability of natural products to confer renal protection by modulating key regulatory nodes of metabolic reprogramming.

Wenru Wang, Han Zhu, Keqin Zhao et al. · 0 citations
Review Open access Sep 2026

Oxidative Stress and Mitochondrial Dysfunction in Chronic Kidney Disease: From Molecular Mechanisms to Biomarkers and Targeted Therapies

Chronic kidney disease (CKD) represents a major global health challenge, affecting more than 10% of the population and contributing substantially to morbidity and premature mortality. Growing evidence identifies oxidative stress and mitochondrial dysfunction as central drivers of renal injury and disease progression across diverse etiologies. The kidney is one of the most mitochondria-rich organs in the body, reflecting the high bioenergetic demands required for tubular reabsorption and metabolic homeostasis. Disruption of mitochondrial oxidative phosphorylation, excessive production of reactive oxygen species (ROS), and impaired mitochondrial quality control mechanisms promote tubular injury, inflammation, and fibrosis. In particular, dysfunction of the electron transport chain, activation of NADPH oxidase isoforms—especially NOX4—and alterations in mitochondrial dynamics create a vicious cycle of oxidative damage and bioenergetic failure. Emerging evidence highlights the importance of mitochondrial quality control pathways, including fusion–fission balance, PINK1/Parkin-mediated mitophagy, and mitochondrial biogenesis regulated by PGC-1α and TFAM. Additional mechanisms include ferroptosis, epigenetic regulation, mitochondrial DNA-mediated innate immune activation, and Na+/K+-ATPase-linked redox signaling. At the translational level, redox and mitochondrial biomarkers and targeted therapies are biologically compelling, but the evidence is uneven: most candidate biomarkers remain insufficiently standardized, and direct mitochondria-targeted interventions are supported predominantly by preclinical studies or small human proof-of-concept trials. This review therefore emphasizes not only mechanistic advances but also conflicting findings, model limitations, and the barriers that currently separate experimental efficacy from clinically meaningful CKD outcomes.

Federica De Luca, Dario Troise, Valentina Camporeale et al. · 0 citations
Review Open access Aug 2026

Redox-Mediated Mitochondrial Dysfunction as a Common Pathogenic Axis in Acute Kidney Injury and Chronic Kidney Disease

Overall, redox-mediated mitochondrial injury represents a shared pathogenic axis and a potential therapeutic target across kidney diseases, and emerging biomarkers and therapeutic strategies targeting oxidative stress and mitochondrial dysfunction are discussed.

Ewelina Młynarska, K. Bojdo, Katarzyna Hossa et al. · 0 citations
Review Open access Aug 2026

Metabolic reprogramming in diabetic complications: mechanisms, pathologies, and molecular evidence from multi-organ studies

A new perspective is provided for understanding why shared metabolic reprogramming in diabetes produces tissue-specific pathological outcomes, including filtration-barrier injury, vascular leakage, impaired wound healing, neuropathic injury, and cardiac dysfunction.

Q. Gong, Wei Zhao, Jing Xia et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.